We believe that every individual deserves the chance for a healthy future, and our daily efforts reflect this belief – shaping a world where health and happiness are within reach for everyone. Together, we're building a brighter tomorrow.
-7CCTJ.jpg)
-INFfS.jpg)
-9aNmH.jpg)
-3gqdM.jpg)
-31Yvo.jpg)
-j5AKO.jpg)
-DLNrr.jpg)
-iFBl-.jpg)
-9-ExQ.jpg)
-qM5-l.jpg)
-oA5w7.jpg)
-gVWiZ.jpg)
-MnHJD.jpg)
-ANfKN.jpg)
-YRJgt.jpg)
-d6Gjt.jpg)
-WedUv.jpg)
-ffXSS.jpg)
Choose Qupha Global for our unwavering commitment to quality and safety in pharmaceutical exports. We provide a diverse array of high-standard formulations that meet rigorous international regulations. Our expertise in intellectual property ensures formulation integrity, while our sensitivity to market needs allows for customized exports tailored to local preferences. With Qupha Global, you engage a trusted global healthcare partner adept at navigating the complexities of international pharmaceutical trade with excellence and reliability.
" Your journey towards optimal health and vitality"
India has emerged as a global leader in generic drugs exports, surpassing $25 billion in 2023. The Indian pharmaceutical industry ranks 3rd worldwide in medicine production by volume. Additionally, India holds the 14th position in the global pharma market value. With Qupha global’s ambitious goals to export pharma formulations and APIs to 50 countries by 2028, this marks a game-changing milestone for the country's pharmaceutical sector.
The booming CRO sector in India is set to reach USD 2.5 billion by 2030, surging at a CAGR of 10.75%. With gross margins soaring at 40-50%, the industry holds lucrative potential. Discover with Qupha global how CRO can generate a remarkable 40-50% return on investment.
Qupha Global excels in Pharma Formulation Export, delivering diverse, high-quality formulations internationally. We uphold strict regulatory compliance and IP rights management, ensuring product safety, efficacy, and integrity. Attuned to local needs, we customize exports, affirming our role as a reliable healthcare industry partner.
India's medical devices imports surged from ₹44,708 crore to ₹63,200 crore between FY 2021-22 and 2020-21, marking a 41% growth. The sector is valued at $11 billion and is expected to reach $50 billion by 2030. With a consistent CAGR of 15% over the past three years, it offers an attractive prospect for investors. The market includes vital segments like Consumables & Disposables (e.g., needles and syringes) where Qupha global is engaged in expanding its vertical.
The medical tourism industry revenue reached $7.4B in 2022; however, it is projected to soar to $43.5B by 2032. The Qupha global aims to collaborate with leading hospitals and doctors in India, with an ambitious goal of association with 100 countries within the next two years.
According to Volza's global export data, the top 3 exporters of surgical items are India, Germany, and the United States. India leads with 50916 shipments; Germany follows with 10293 shipments; and the United States ranks third with 6431 shipments. With India dominating exports by a significant margin, emphasizing its prominent global role in meeting demand, Qupha global is aiming to enter the export market in surgical items.
Qupha Global bridges healthcare gaps with top-tier pharma exports, ensuring communities worldwide access to effective and safe therapeutic treatments.
Qupha Global embodies the pinnacle of excellence and integrity in the Pharma Formulation Export industry. As a visionary leader, we export premium pharmaceutical formulations to meet the global demand for quality medications. Our extensive services cover various therapeutic areas, ensuring healthcare professionals and patients worldwide have access to our products. Rigorous adherence to international regulations ensures safety and efficacy. Our knowledgeable team proactively secures Intellectual Property rights, while customizing exports to fit local market needs. Qupha Global's steadfast commitment to quality has established us as a reliable partner in global healthcare, advancing medication accessibility everywhere.
Founder Director & CEO
MBA, BSc
12 + years of exposure to Entrepreneurship and overall 21+ years of experience.
Companies : Nicholas Piramal, Unichem Labs, ICICI Health vertical
-BCg8u.jpg)
Co-Founder and Director
MSc Chemistry
Companies : Cipla, Apotex, Tulips R&D.
Faced USFDA,
MHRA,TGA,
Health Canada and WHO Audits
-pLzVZ.jpg)
Digital Health Consultant
-IemxQ.jpg)
Pathologist
-moR6J.jpg)
Opthamalogists
-KTRV9.jpg)
Anesthesiologist
-24gD8.jpg)
General Surgeon
-EMeUG.jpg)
Orthopaedician
Here are the answers to some frequently asked questions
Qupha Global is distinguished by our commitment to quality and safety. We provide diverse, high-standard formulations that not only adhere to strict international regulatory standards but also meet specific local market needs. With meticulous management of Intellectual Property rights, we ensure both the integrity of our products and the trust of our clients.
Our exported products undergo stringent compliance checks with international regulatory standards. This guarantees their safety and efficacy. Additionally, our experienced team dedicates itself to maintaining the high quality of our pharmaceuticals that healthcare markets globally can rely on.
Absolutely. We understand the importance of catering to unique market preferences and demands. Qupha Global takes pride in our ability to customize our exports, ensuring they align with the cultural and therapeutic needs of the local populations we serve.
"Discover Our Location Easily with Our Map – Get Directions Now!"
Move to Top